Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Reduced Intensity Conditioning

Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cells

Bone Marrow Transplantation volume 33, pages 491–497 (2004)Cite this article

Summary:

Nonmyeloablative allogeneic stem cell transplantation (NST) is thought to be an immunologic therapy in which donor T cells mediate a graft-versus-tumor effect. We recently reported the clinical outcome of a phase II trial of NST in metastatic renal cell carcinoma (RCC). However, the immune response correlates of clinical activity remain unknown. We now describe the analysis of T-cell subsets and T-cell cytokine-producing potential for those patients evaluable for immune monitoring. The incidence of graft-versus-host disease (GVHD) correlated with clinical outcome, with all responders exhibiting chronic GVHD. Following initial tapering of immunosuppression, an increase in the total numbers of CD8+ T cells but not CD4+ T cells was observed among responders compared to nonresponders. In addition, a greater ratio of CD8+ to CD4+ T cells producing IFN-γ and IL-2 was seen in clinical responders at the time when clinical responses were first detected (day 180 after transplantation). Our results support the hypothesis that the antitumor effects of NST may be mediated by IFN-γ-producing CD8+ T cells, and indicate that isolation of putative tumor antigen-specific T cells, ideally, should be pursued around day +180.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Motzer RJ, Russo P . Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408–417.

    Article  CAS  PubMed  Google Scholar 

  2. Fisher RI, Rosenberg SA, Fyfe G . Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 (Suppl 1): S55–S57.

    PubMed  Google Scholar 

  3. Koretz MJ, Lawson DH, York RM et al. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 1991; 126: 898–903.

    Article  CAS  PubMed  Google Scholar 

  4. Sullivan KM, Fefer A, Witherspoon R et al. Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. Prog Clin Biol Res 1987; 244: 391–399.

    CAS  PubMed  Google Scholar 

  5. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    CAS  PubMed  Google Scholar 

  6. Levine JE, Braun T, Penza SL et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405–412.

    Article  CAS  PubMed  Google Scholar 

  7. Weiss L, Weigensberg M, Morecki S et al. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunol Immunother 1990; 31: 236–242.

    Article  CAS  PubMed  Google Scholar 

  8. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750–758.

    Article  CAS  PubMed  Google Scholar 

  9. Childs RW, Clave E, Tisdale J et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044–2049.

    Article  CAS  PubMed  Google Scholar 

  10. Rini BI, Zimmerman T, Stadler WM et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20: 2017–2024.

    Article  PubMed  Google Scholar 

  11. Rini BI, Zimmerman TM, Gajewski TF et al. Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol 2001; 165: 1208–1209.

    Article  CAS  PubMed  Google Scholar 

  12. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234–4236.

    Article  CAS  PubMed  Google Scholar 

  13. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234–3241.

    CAS  PubMed  Google Scholar 

  14. Riddell SR, Murata M, Bryant S, Warren EH . Minor histocompatibility antigens – targets of graft versus leukemia responses. Int J Hematol 2002; 76 (Suppl 2): 155–161.

    Article  PubMed  Google Scholar 

  15. Fallarino F, Uyttenhove C, Boon T, Gajewski TF . Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol 1996; 156: 1095–1100.

    CAS  PubMed  Google Scholar 

  16. Fallarino F, Gajewski TF . Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 1999; 163: 4109–4113.

    CAS  PubMed  Google Scholar 

  17. Glasebrook AL, Fitch FW . Alloreactive cloned T cell lines. I. Interactions between cloned amplifier and cytolytic T cell lines. J Exp Med 1980; 151: 876–895.

    Article  CAS  PubMed  Google Scholar 

  18. Shrikant P, Khoruts A, Mescher MF . CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 1999; 11: 483–493.

    Article  CAS  PubMed  Google Scholar 

  19. Laux I, Khoshnan A, Tindell C et al. Response differences between human CD4(+) and CD8(+) T-cells during CD28 costimulation: implications for immune cell-based therapies and studies related to the expansion of double-positive T-cells during aging. Clin Immunol 2000; 96: 187–197.

    Article  CAS  PubMed  Google Scholar 

  20. Appelbaum FR, Sandmaier B . Sensitivity of renal cell cancer to nonmyeloablative allogeneic hematopoietic cell transplantations: unusual or unusually important? J Clin Oncol 2002; 20: 1965–1967.

    Article  PubMed  Google Scholar 

  21. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.

    Article  CAS  PubMed  Google Scholar 

  22. Trinchieri G . Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251–276.

    Article  CAS  PubMed  Google Scholar 

  23. Atkinson K, Hansen JA, Storb R et al. T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets. Blood 1982; 59: 1292–1298.

    CAS  PubMed  Google Scholar 

  24. Fujimaki K, Maruta A, Yoshida M et al. Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 27: 1275–1281.

    Article  CAS  PubMed  Google Scholar 

  25. Kircher B, Stevanovic S, Urbanek M et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol 2002; 117: 935–939.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank W Stadler for advice and patient recruitment, and K Van Besien for helpful discussion. This work was supported in part by a grant from the Cancer Treatment Research Foundation, Arlington Heights, IL.

Author information

Author notes

  1. B I Rini: Current affiliation: The University of California, San Francisco

Authors and Affiliations

  1. Department of Pathology, The University of Chicago, IL, USA

    H Harlin, M Mahowald & T F Gajewski

  2. Department of Medicine, Section of Hematology/Oncology, The University of Chicago, IL, USA

    A S Artz, B I Rini, T Zimmerman, N J Vogelzang & T F Gajewski

  3. Committees on Immunology and Cancer Biology, The University of Chicago, IL, USA

    T F Gajewski

Authors
  1. H Harlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A S Artz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Mahowald
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B I Rini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Zimmerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N J Vogelzang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T F Gajewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T F Gajewski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harlin, H., Artz, A., Mahowald, M. et al. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cells. Bone Marrow Transplant 33, 491–497 (2004). https://doi.org/10.1038/sj.bmt.1704385

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704385

Keywords

This article is cited by

Search

Advanced search

Quick links